Early Phase 1 N=8 Effect of Probenecid on Synovial Fluid ATP Levels in CPPD
Calcium Pyrophosphate Deposition Disease
Primary: ATP Levels in Synovial Fluid — 4.4; 31.4 nanomoles/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=13 Treatment for Calcium Phosphate Kidney Stone Disease
Calcium Phosphate Kidney Stones
Primary: Urinary Calcium Phosphate Saturation — 2.38; 1.97; 2.19 no units
Phase 3 N=68 Bone Properties in Hypoparathyroidism: Effects of PTH
Hypoparathyroidism
Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation
N/A N=12 PTH And Calcium Responses to Exercise in Older Adults Experiment 2 (PACE Sr. 2)
Osteoporosis
Primary: Change in Parathyroid Hormone (PTH) — 8.5; 20.0 pg/mL
N/A N=3 Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease
Phosphorus and Calcium Disorders · Chronic Kidney Disease Mineral and Bone Disorder · Chronic Kidney Diseases
Primary: Fractional Calcium Absorption — 0.30; 0.42 fraction of 1.00
Phase 2 N=7 Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)
Arterial Calcification · CD73 Deficiency
Primary: Ankle-brachial Index at Rest at Pre-treatment, On-treatment and Post-treatment of Etidronate in Participants Diagnosed With ACDC — 0.5741; 0.5411; 0.5222; 0.5266 score…
Phase 2 N=241 Adding Phosphorus to Osteoporosis Drug Treatment
Osteoporosis · Osteopenia
Primary: Lumbar Spine and Hip BMD, Measured as Grams Per Square Centimeter. — 0.76; 0.78; 0.88; 0.86 g/cm2
Phase 2 N=44 Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)
Pseudoxanthoma Elasticum
Primary: Von Kossa Staining Per Unit Area of Dermis — -0.0033; 0.0010; 0.0087; 0.0123 microns
Phase 4 N=87 Prophylaxis of Periprosthetic Joint Infections With Calcium Sulfate Beads in Patients With Non-modifiable Risk Factors.
Infection
Primary: Partipants Achieving a Lower Hip or Knee Periprosthetic Joint Infection Rate With Local Versus Conventional Intravenous Antibiotic Prophilaxys, Measured With CRP, ERS in…
Phase 3 N=15 A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis
Palmoplantaris Pustulosis
Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change
Phase 3 N=221 An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.
Fibrodysplasia Ossificans Progressiva
Primary: Annualized New Heterotopic Ossification (HO) — 9427.1; 23720.2 cubic millimeters (mm^3)
Phase 2 N=90 A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis
Palmoplantaris Pustulosis
Primary: Percentage of Participants Who Achieve a PPPASI-50 at Week 16 — 40.9; 78.3 Percentage of Partcipants — p=0.0003
Phase 2 N=395 Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis
Osteoarthritis, Knee
Primary: Change in Minimum Joint Space Width in the Medial Compartment of the Tibiofemoral Joint of the Signal Knee After 1 Year of Treatment — -0.1361; -0.0442; -0.2261; -0.2000…
N/A N=12 Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease
Chronic Kidney Disease
Primary: Calcium Balance — 61; 508 mg/d calcium
Phase 2 N=65 A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
Pseudoxanthoma Elasticum
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) in Participants Receiving DS-1211b — 8; 7; 6; 6 Participants
Phase 2 N=30 Role Of Phosphorus And FGF 23 In Patients With Dent Disease
Dent Disease
Primary: Change in Urine Total Protein — 1681; 59 mg/day
N/A N=36 Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)
Polycystic Ovarian Syndrome · Vitamin D Deficiency
Primary: Serum HbA1C at 3 Months — 5.55 percentage
Phase 2 N=20 Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions
Gout
Primary: CT Bone Erosion Score — 6.6; 7.0 Score on a scale
Phase 3 N=14 Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
Dermatomyositis · Idiopathic Inflammatory Myopathies
Primary: Change in Calcinosis Activity Visual Analogue Scale Score — -3.45 Units on a scale
N/A N=29 Calcium Absorption in Patients With Rothmund-Thomson Syndrome
Rothmund-Thomson Syndrome
Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
N/A N=42 Pioglitazone on Pancreatic Steatosis and Bone Health
Obesity · Type 2 Diabetes
Primary: Pancreatic Fat Content — 9.6; 13.0 Percentage of fat
Phase 2 N=165 Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis
Osteoporosis
Primary: Percent Change in Lumbar Spine Bone Mineral Density (BMD): Baseline to Week 24 — -0.33; 2.96; 3.47; 4.97 percent change
Phase 2 N=100 RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints
Hand Osteoarthritis
Primary: Total Ghent University Scoring System (GUSS) of Target Joints at Week 24 — 162.2; 153.3 units on a scale — p=0.024
N/A N=15 Intra Articular Injections With Platelet Rich Plasma in Patients With Juvenile Osteochondritis Dissecans of the Knee
Osteochondritis Dissecans
Primary: Greater Cartilage Healing Measured by Glycosaminoglycan Content on dGEMRIC MRI
Phase 4 N=44 Vitamin D and Coronary Calcification Study
Chronic Kidney Disease · Vitamin D Deficiency · Coronary Calcification
Primary: Coronary Artery (CAC) Score Progression — 74.38; 106.32 Agatston units
Phase 2 N=27 Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
Hypoparathyroidism
Primary: Serum Calcium Level — 2; 1.92 mmol/liter
Phase 3 N=65 Hyper- and Hypokalemic Periodic Paralysis Study
Hyperkalemic Periodic Paralysis · Hypokalemic Periodic Paralysis
Primary: HYP Attack Rate — 0.9; 4.8 attacks per week
Phase 2 N=7 A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations
Autosomal Dominant Hypocalcemia (ADH)
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 3; 1 participants
N/A N=156 Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total Knee Arthroplasty
Prosthetic Joint Infection
Primary: Calprotectin POC — 1; 3; 52; 29 Participants
Phase 3 N=30 Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
Hyperparathyroidism · Chronic Kidney Disease
Primary: Fractional Change in [PTH] in CKD After a 4-week Course of Sevelamer Carbonate — -11.7; 16.4 percentage of baseline [PTH]